CTLA4 antibody (AA 75-170) (AbBy Fluor® 350)

Catalog No. ABIN1693744

This Rabbit Polyclonal antibody specifically detects CTLA4 in FACS, WB and IF (p). It exhibits reactivity toward Human, Mouse and Rat.

Quick Overview for CTLA4 antibody (AA 75-170) (AbBy Fluor® 350) (ABIN1693744)

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CTLA4 antibody is conjugated to AbBy Fluor® 350

Application: Flow Cytometry (FACS), Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Product Details anti-CTLA4 Antibody (AbBy Fluor® 350)

Binding Specificity: AA 75-170

Cross-Reactivity: Human, Mouse, Rat

Predicted Reactivity: Dog,Cow,Sheep,Rabbit

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human CTLA-4/CD152

Isotype: IgG

Application Details

Application Notes: FCM 1:20-100
IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for CTLA4

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Alternative Name: CTLA4

Background:

Synonyms: CD, GSE, GRD4, CD152, CTLA-4, IDDM12, CELIAC3, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA4

Background: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.

Gene ID: 1493

UniProt: P16410

Pathways: Cancer Immune Checkpoints